HRP20130688T1 - Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha - Google Patents
Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alphaInfo
- Publication number
- HRP20130688T1 HRP20130688T1 HRP20130688AT HRP20130688T HRP20130688T1 HR P20130688 T1 HRP20130688 T1 HR P20130688T1 HR P20130688A T HRP20130688A T HR P20130688AT HR P20130688 T HRP20130688 T HR P20130688T HR P20130688 T1 HRP20130688 T1 HR P20130688T1
- Authority
- HR
- Croatia
- Prior art keywords
- methods
- treating cancer
- pi3k alpha
- pyridopyrimidinone
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92289907P | 2007-04-10 | 2007-04-10 | |
| PCT/US2008/004573 WO2008124161A1 (en) | 2007-04-10 | 2008-04-09 | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130688T1 true HRP20130688T1 (en) | 2013-09-30 |
Family
ID=39627802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130688AT HRP20130688T1 (en) | 2007-04-10 | 2008-04-09 | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8513266B2 (enExample) |
| EP (1) | EP2139484B9 (enExample) |
| JP (3) | JP2010523670A (enExample) |
| KR (1) | KR101626435B1 (enExample) |
| CN (2) | CN101715345A (enExample) |
| AU (1) | AU2008236562B2 (enExample) |
| BR (1) | BRPI0810206A2 (enExample) |
| CA (1) | CA2683641C (enExample) |
| CO (1) | CO6251254A2 (enExample) |
| CR (1) | CR11100A (enExample) |
| DK (1) | DK2139484T3 (enExample) |
| DO (1) | DOP2009000243A (enExample) |
| EA (1) | EA020022B1 (enExample) |
| EC (1) | ECSP099724A (enExample) |
| ES (1) | ES2430614T3 (enExample) |
| HN (1) | HN2009003002A (enExample) |
| HR (1) | HRP20130688T1 (enExample) |
| IL (1) | IL201284A (enExample) |
| MA (1) | MA31358B1 (enExample) |
| ME (1) | ME00936B (enExample) |
| MX (1) | MX2009010930A (enExample) |
| MY (1) | MY150697A (enExample) |
| NZ (1) | NZ580110A (enExample) |
| PL (1) | PL2139484T3 (enExample) |
| PT (1) | PT2139484E (enExample) |
| RS (1) | RS52939B (enExample) |
| SI (1) | SI2139484T1 (enExample) |
| TN (1) | TN2009000400A1 (enExample) |
| UA (1) | UA100979C2 (enExample) |
| WO (1) | WO2008124161A1 (enExample) |
| ZA (1) | ZA200906764B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200726767A (en) * | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
| RS53627B1 (sr) * | 2005-10-07 | 2015-04-30 | Exelixis Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova upotreba kao inhibitora fosfatidilinozitol3-kinaze |
| NZ594628A (en) * | 2005-10-07 | 2013-04-26 | Exelixis Inc | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka |
| WO2008021389A2 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| SA08280783B1 (ar) * | 2007-01-11 | 2011-04-24 | استرازينيكا ايه بي | مشتقات بيريدوبيريميدين كمثبطات pde4 |
| RS52939B (sr) | 2007-04-10 | 2014-02-28 | Exelixis Inc. | Postupci za lečenje kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa |
| HRP20131081T1 (hr) * | 2007-04-11 | 2013-12-20 | Exelixis Inc. | Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera |
| US8697694B2 (en) | 2008-08-20 | 2014-04-15 | Merck Sharp & Dohme Corp. | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| JP5674661B2 (ja) | 2008-08-20 | 2015-02-25 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | エチニル置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用 |
| AU2009282574B2 (en) * | 2008-08-20 | 2014-08-21 | Merck Sharp & Dohme Corp. | Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| WO2010022126A1 (en) | 2008-08-20 | 2010-02-25 | Schering Corporation | Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| AR080151A1 (es) | 2010-02-09 | 2012-03-14 | Exelixis Inc | Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia |
| US20130156768A1 (en) * | 2010-08-26 | 2013-06-20 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases |
| JP5792819B2 (ja) | 2010-09-14 | 2015-10-14 | エクセリクシス， インク． | Ｐｉ３ｋ−デルタの阻害剤ならびにそれらの使用法および製造法 |
| WO2012065019A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of p13k alpha |
| WO2012158960A2 (en) * | 2011-05-17 | 2012-11-22 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Melanocortin 1 receptor ligands and methods of use |
| TW201306842A (zh) * | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 |
| CN104010494B (zh) * | 2011-07-28 | 2017-07-04 | 霍夫曼-拉罗奇有限公司 | Pik3ca h1047r敲入非人动物乳腺癌模型 |
| WO2013056067A1 (en) * | 2011-10-13 | 2013-04-18 | Exelixis, Inc. | Compounds for use in the treatment of basal cell carcinoma |
| EA201490905A1 (ru) | 2011-11-01 | 2014-11-28 | Экселиксис, Инк. | N-(3-{[(3-{[2-хлор-5-(метокси)фенил]амино}хиноксалин-2-ил)амино]сульфонил}фенил)-2-метилаланинамид как ингибитор фосфатидилинозитол-3-киназы для лечения лимфопролиферативных злокачественных заболеваний |
| US9682141B2 (en) | 2011-11-11 | 2017-06-20 | Intellikine Llc | Combination of kinase inhibitors and uses thereof |
| JP2015503568A (ja) * | 2011-12-27 | 2015-02-02 | カドモン コーポレイション，リミティド ライアビリティ カンパニー | トラスツズマブに不応性の乳癌の治療方法 |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| SG11201408679XA (en) | 2012-06-26 | 2015-01-29 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| US8980259B2 (en) * | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
| MY176031A (en) | 2012-08-07 | 2020-07-22 | Array Biopharma Inc | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
| US11491154B2 (en) | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| US9950194B2 (en) | 2014-09-09 | 2018-04-24 | Mevion Medical Systems, Inc. | Patient positioning system |
| AU2017226389B2 (en) | 2016-03-04 | 2023-02-02 | Taiho Pharmaceutical Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| ES2876411T3 (es) * | 2016-08-15 | 2021-11-12 | Pfizer | Inhibidores de piridopirimdinona CDK2/4/6 |
| JP7027699B2 (ja) * | 2017-05-09 | 2022-03-02 | 住友ゴム工業株式会社 | タイヤトレッドおよびタイヤ |
| CN118903436A (zh) | 2018-01-31 | 2024-11-08 | 德西费拉制药有限责任公司 | 治疗肥大细胞增多症的组合疗法 |
| JP2021512105A (ja) | 2018-01-31 | 2021-05-13 | デシフェラ・ファーマシューティカルズ，エルエルシー | 消化管間質腫瘍の治療のための併用療法 |
| PL3769765T3 (pl) | 2018-03-19 | 2024-06-10 | Taiho Pharmaceutical Co., Ltd. | Kompozycja farmaceutyczna zawierająca alkilosiarczan sodu |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| NZ784949A (en) | 2019-08-12 | 2025-09-26 | Deciphera Pharmaceuticals Llc | Ripretinib for treating gastrointestinal stromal tumors |
| JP7677646B2 (ja) * | 2019-12-10 | 2025-05-15 | ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー | 複製タンパク質ａ（ｒｐａ）－ｄｎａ相互作用阻害剤 |
| FI4084778T3 (fi) | 2019-12-30 | 2023-12-18 | Deciphera Pharmaceuticals Llc | Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi |
| SMT202400484T1 (it) | 2019-12-30 | 2025-01-14 | Deciphera Pharmaceuticals Llc | Composizioni di 1-(4-bromo-5-(1-etil-7-(metilammino)-2-osso-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilurea |
| KR102195221B1 (ko) | 2019-12-31 | 2020-12-24 | 서울대학교산학협력단 | 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물 |
| CN111358952B (zh) * | 2020-04-15 | 2022-03-15 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种抗肿瘤药物组合物及其制剂和应用 |
| WO2023092104A1 (en) * | 2021-11-18 | 2023-05-25 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7019002B2 (en) * | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
| EP1521747B1 (en) | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
| BRPI0507852A (pt) * | 2004-02-18 | 2007-07-10 | Warner Lambert Co | 2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas |
| WO2005105801A1 (en) | 2004-05-04 | 2005-11-10 | Warner-Lambert Company Llc | Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents |
| WO2007004698A1 (ja) * | 2005-07-06 | 2007-01-11 | Sbc Corporation | 漏洩電流検出装置及び漏洩電流検出方法 |
| CN102746298A (zh) * | 2005-10-07 | 2012-10-24 | 埃克塞里艾克西斯公司 | PI3Kα的吡啶并嘧啶酮抑制剂 |
| RS53627B1 (sr) * | 2005-10-07 | 2015-04-30 | Exelixis Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova upotreba kao inhibitora fosfatidilinozitol3-kinaze |
| NZ594628A (en) | 2005-10-07 | 2013-04-26 | Exelixis Inc | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka |
| WO2008021389A2 (en) * | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| WO2008032162A1 (en) * | 2006-09-15 | 2008-03-20 | Pfizer Products Inc. | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
| RS52939B (sr) | 2007-04-10 | 2014-02-28 | Exelixis Inc. | Postupci za lečenje kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa |
| CN101711249A (zh) | 2007-04-11 | 2010-05-19 | 埃克塞里艾克西斯公司 | 作为PI3K-α的抑制剂用于治疗癌症的吡啶并[2,3-D]嘧啶-7-酮化合物 |
| HRP20131081T1 (hr) * | 2007-04-11 | 2013-12-20 | Exelixis Inc. | Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera |
| AU2008239655B2 (en) | 2007-04-11 | 2013-06-20 | Exelixis, Inc. | Pyrido (2, 3-d) pyrimidin-7-one compounds as inhibitors of PI3k-alpha for the treatment of cancer |
| WO2010039740A1 (en) * | 2008-09-30 | 2010-04-08 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR |
-
2008
- 2008-04-09 RS RS20130384A patent/RS52939B/sr unknown
- 2008-04-09 BR BRPI0810206-6A2A patent/BRPI0810206A2/pt not_active IP Right Cessation
- 2008-04-09 KR KR1020097023351A patent/KR101626435B1/ko not_active Expired - Fee Related
- 2008-04-09 MX MX2009010930A patent/MX2009010930A/es active IP Right Grant
- 2008-04-09 EP EP08742677.1A patent/EP2139484B9/en active Active
- 2008-04-09 PT PT87426771T patent/PT2139484E/pt unknown
- 2008-04-09 ES ES08742677T patent/ES2430614T3/es active Active
- 2008-04-09 JP JP2010503045A patent/JP2010523670A/ja active Pending
- 2008-04-09 UA UAA200911419A patent/UA100979C2/ru unknown
- 2008-04-09 EA EA200970932A patent/EA020022B1/ru not_active IP Right Cessation
- 2008-04-09 ME MEP-2009-303A patent/ME00936B/me unknown
- 2008-04-09 CN CN200880018725A patent/CN101715345A/zh active Pending
- 2008-04-09 DK DK08742677.1T patent/DK2139484T3/da active
- 2008-04-09 MY MYPI20094214 patent/MY150697A/en unknown
- 2008-04-09 HR HRP20130688AT patent/HRP20130688T1/hr unknown
- 2008-04-09 US US12/595,219 patent/US8513266B2/en not_active Expired - Fee Related
- 2008-04-09 CA CA2683641A patent/CA2683641C/en not_active Expired - Fee Related
- 2008-04-09 SI SI200831004T patent/SI2139484T1/sl unknown
- 2008-04-09 AU AU2008236562A patent/AU2008236562B2/en not_active Ceased
- 2008-04-09 PL PL08742677T patent/PL2139484T3/pl unknown
- 2008-04-09 CN CN201210032620.4A patent/CN102727498B/zh not_active Expired - Fee Related
- 2008-04-09 NZ NZ580110A patent/NZ580110A/en not_active IP Right Cessation
- 2008-04-09 WO PCT/US2008/004573 patent/WO2008124161A1/en not_active Ceased
-
2009
- 2009-09-29 ZA ZA200906764A patent/ZA200906764B/xx unknown
- 2009-09-30 TN TNP2009000400A patent/TN2009000400A1/fr unknown
- 2009-10-01 IL IL201284A patent/IL201284A/en active IP Right Grant
- 2009-10-09 DO DO2009000243A patent/DOP2009000243A/es unknown
- 2009-10-09 HN HN2009003002A patent/HN2009003002A/es unknown
- 2009-11-02 MA MA32318A patent/MA31358B1/fr unknown
- 2009-11-09 CO CO09126924A patent/CO6251254A2/es not_active Application Discontinuation
- 2009-11-09 CR CR11100A patent/CR11100A/es unknown
- 2009-11-09 EC EC2009009724A patent/ECSP099724A/es unknown
-
2013
- 2013-09-19 JP JP2013194611A patent/JP2014034576A/ja active Pending
-
2014
- 2014-03-24 JP JP2014059561A patent/JP2014139217A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2139484T3 (pl) | Sposoby leczenia raka z zastosowaniem pirydopirymidynonów jako inhibitorów PI3K alfa | |
| SI2483278T1 (sl) | Inhibitorske spojine benzoksazepina pi3k in njihova uporaba pri zdravljenju raka | |
| ZA201007524B (en) | Purine pi3k inhibitor compounds and methods of use | |
| EP2211854A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS | |
| EP2318406A4 (en) | THIOSEMICARBAZONHERMAL COMPOUNDS AND CANCER TREATMENT PROCEDURES | |
| IL218800A0 (en) | Benzoxepin pi3k inhibitor compounds and methods of use | |
| IL219253A (en) | Benzodiazepine inhibiting bromodomain for cancer treatment | |
| IL197315A0 (en) | Treatment of cancer | |
| EP2136847A4 (en) | OLIGORIBONUCLEOTIDE HEMMER OF NRF2 AND METHOD OF USE THEREOF FOR THE TREATMENT OF CANCER | |
| PL2340042T3 (pl) | Sposoby i kompozycje do leczenia raka | |
| ZA201006988B (en) | Method and compositions for treatment of cancer | |
| IL196208A0 (en) | Methods for cancer treatment using tak1 inhibitors | |
| EP2242501A4 (en) | THERAPEUTIC INHIBITORS OF PAI-I FUNCTION AND METHODS OF USE | |
| IL199689A0 (en) | Compounds and method for treatment of cancer | |
| EP2176406A4 (en) | COMPOSITIONS AND METHOD FOR CANCER TREATMENT | |
| PL2187967T3 (pl) | Sposoby i kompozycje do leczenia raka | |
| IL202307A0 (en) | Multikinase inhibitors for use in the treatment of cancer | |
| EP2225226A4 (en) | COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER | |
| IL205452A0 (en) | Methods of treating scleroderma | |
| IL205339A0 (en) | Compounds and methods for the treatment of cancer | |
| IL196361A0 (en) | Combination methods of treating cancer | |
| GB0600903D0 (en) | Treatment of cancer | |
| ZA200904158B (en) | Methods of cancer treatment with IGF1R inhibitors | |
| GB0712513D0 (en) | Treatment of cancer | |
| GB0622471D0 (en) | Use of reversine and analogs for treatment of cancer |